首页> 美国卫生研究院文献>AAPS PharmSciTech >Design Characterization and Evaluation of Meloxicam Gel Prepared by Suspension and Solution Polymerization Using Solubility Parameter as the Basis for Development
【2h】

Design Characterization and Evaluation of Meloxicam Gel Prepared by Suspension and Solution Polymerization Using Solubility Parameter as the Basis for Development

机译:以溶解度参数为开发依据的悬浮和溶液聚合制备的美洛昔康凝胶的设计表征和评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Meloxicam gel was designed based on the matching of the solubility parameter (δ) of the drug with that of the polymer and subsequently with skin for improved dermal delivery of meloxicam. The δ of meloxicam (11.48 (cal/cm3)0.5) determined by solubility measurement was matched statistically to the solubility parameter of monomers, n-vinyl-2-pyrrolidone, polyvinyl alcohol (PVA), hydroxyl ethyl methacrylate, ethylene glycol methacrylate (EGMA) determined by intrinsic viscosity measurement. Consequently gels were formulated by polymerization in selected solvent blend of water/ethyl acetate (20:80) in which the drug showed maximum solubility. Thus, F1–F16 formulations designed were evaluated for physicochemical properties, textural analysis, and in vitro drug release. On the basis of optimum characteristics, F2 (PVA, δ = 16.96 (cal/cm3)0.5) and F8 (EGMA, δ = 18.35 (cal/cm3)0.5) formulated by suspension polymerization were selected and subjected to skin irritation and topical anti-inflammatory studies. The formulation F8 demonstrated significant (p < 0.05) of anti-inflammatory activity in comparison to marketed piroxicam gel and was free from irritation.
机译:美洛昔康凝胶的设计基于药物的溶解度参数(δ)与聚合物的溶解度参数(δ)以及随后与皮肤的溶解度参数匹配,以改善美洛昔康的皮肤递送。通过溶解度测量确定的美洛昔康的δ(11.48(cal / cm 3 0.5 )与单体n-乙烯基-2-吡咯烷酮的溶解度参数统计匹配,通过特性粘度测量法测定聚乙烯醇(PVA),甲基丙烯酸羟乙酯,甲基丙烯酸乙二醇酯(EGMA)。因此,通过在水/乙酸乙酯(20:80)的选定溶剂混合物中聚合来配制凝胶,其中药物显示出最大溶解度。因此,对设计的F1-F16制剂进行了理化性质,质地分析和体外药物释放的评估。根据最佳特性,F2(PVA,δ= 16.96(cal / cm 3 0.5 )和F8(EGMA,δ= 18.35(cal / cm 3 0.5 )进行皮肤刺激和局部抗炎研究。与市售的吡罗昔康凝胶相比,制剂F8表现出显着的抗炎活性(p <0.05),并且没有刺激性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号